Search research articles
Contact Us
Filters
Showing results (31-40 of 36) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 36 results.
Journal of Enzyme Inhibition and Medicinal Chemistry
|
January 20, 2021
Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates
Hyun Myung Lee, Rudolf Andrys, Jakub Jonczyk, et al.
Bioorganic Chemistry
|
April 23, 2026
The structure-activity relationship study of torkinib derivatives as mTOR inhibitors with senolytic and STAT3 inhibitory activities
Patrik Oleksak, David Rysanek, Marketa Vancurova, et al.
European Journal of Medicinal Chemistry
|
June 30, 2023
Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation
Ondrej Benek, Michaela Vaskova, Marketa Miskerikova, et al.
Cancer Cell International
|
May 7, 2026
In silico screening, synthesis, and biological evaluation of pyrazolopyrimidine-derived mTOR inhibitors for anticancer and senomorphic effects
David Rysanek, Zofia Chrienova, Dorota Stary, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 2, 2023
Frentizole derivatives with mTOR inhibiting and senomorphic properties
Zofia Chrienova, David Rysanek, Josef Novak, et al.
Journal of Medicinal Chemistry
|
August 8, 2025
Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors
Svit Ferjančič Benetik, Matic Proj, Damijan Knez, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 36) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 36 results.
Journal of Enzyme Inhibition and Medicinal Chemistry
|
January 20, 2021
Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates
Hyun Myung Lee, Rudolf Andrys, Jakub Jonczyk, et al.
Bioorganic Chemistry
|
April 23, 2026
The structure-activity relationship study of torkinib derivatives as mTOR inhibitors with senolytic and STAT3 inhibitory activities
Patrik Oleksak, David Rysanek, Marketa Vancurova, et al.
European Journal of Medicinal Chemistry
|
June 30, 2023
Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation
Ondrej Benek, Michaela Vaskova, Marketa Miskerikova, et al.
Cancer Cell International
|
May 7, 2026
In silico screening, synthesis, and biological evaluation of pyrazolopyrimidine-derived mTOR inhibitors for anticancer and senomorphic effects
David Rysanek, Zofia Chrienova, Dorota Stary, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 2, 2023
Frentizole derivatives with mTOR inhibiting and senomorphic properties
Zofia Chrienova, David Rysanek, Josef Novak, et al.
Journal of Medicinal Chemistry
|
August 8, 2025
Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors
Svit Ferjančič Benetik, Matic Proj, Damijan Knez, et al.
Page
of 4